Qilu Pharmaceutical and Aikang Pharma Announce Strategic Collaboration on ADHD Drug Aizhida®

(Source: Seeking Truth Medicine Society)

On March 3, ArkBio announced, in collaboration withQilu PharmaceuticalOfficially reached a commercial cooperation, both parties will jointly promote Aizhida®(Compound Lusiloperidate Hydrochloride Capsules)The Commercialization Process in China, for ChinaAttention Deficit Hyperactivity Disorder（ADHD）Provide patients with better treatment options.

According to the agreement, Qilu Pharmaceutical will obtain ArkBio's new ADHD treatment drug, Aizhida®.Mainland ChinaRegion(Excluding Hong Kong, Macao, and Taiwan regions)The exclusive commercialization rights. ArkBio will receive up to470 million yuanMilestone payments, in addition to royalties based on future net sales, etc.

Aizhida® isThe world's first and currently onlyContaining Immediate-Release Dexmethylphenidate（d-MPH）And the prodrug Esil R-Phenylmethylate（SDX）Compound preparation. This drug was approved for marketing in the United States in March 2021 and in China on December 30, 2025.Approved for Marketing in China，For the treatment of ADHD patients aged 6 years and above。

The Market Potential for ADHD Medications is Enormous. The prevalence of ADHD among children and adolescents in China is approximately 6.4%, with a total patient population exceeding 23 million. However, currently, there are limited options for ADHD treatment drugs in China. Some patients struggle to adhere to treatment due to insufficient efficacy, side effects, or inconvenient medication usage, indicating significant unmet clinical needs.

As a novel compound formulation of methylphenidate, ArkBio® directly addresses existing treatment pain points and becomesChina's FirstADHD Treatment Drug with Both Rapid Onset and Long-Lasting Control Fills Clinical Gap in This Field.

The content of the article is for reference only and does not constitute investment advice. Investors who take actions based on this information bear their own risks. The article maintains a neutral stance on the statements and viewpoints presented, and does not provide any express or implied guarantees regarding the accuracy, reliability, or completeness of the content included. Readers are advised to use it solely as a reference and assume full responsibility for their actions.